Monopar Therapeutics 8-K

What Happened
Monopar Therapeutics (MNPR) filed a Form 8-K on March 2, 2026, under Regulation FD to announce the appointment of Susan Rodriguez as Chief Commercial and Strategy Officer. The company furnished a press release announcing the appointment as Exhibit 99.1 to the filing.

Key Details

• Company: Monopar Therapeutics (ticker: MNPR).
• Event: Appointment of Susan Rodriguez as Chief Commercial and Strategy Officer.
• Filing date: March 2, 2026; announcement made via press release (Exhibit 99.1).
• Disclosure type: Regulation FD disclosure furnished on Form 8-K; press release incorporated by reference.

Why It Matters
Leadership changes in commercial and strategy roles are relevant to investors because they relate directly to how the company plans to bring products to market and execute strategic plans. Monopar’s public disclosure via Form 8-K (Regulation FD) ensures all investors receive the appointment information at the same time. The filing does not include additional financial details or other corporate actions.